14, Oct 2026
Centalion and Komgo Bring Agentic AI into Live Treasury Operations
AI Treasury Agent built by Centalion on Komgo’s Konsole via MCP connector cuts trade finance instruments processing times while keeping governance and human approval fully in place
GENEVA, Oct. 14, 2026 /PRNewswire/ — Centalion Group, one of the world’s largest independent commodity trading companies, and Komgo, a leading digital trade finance platform provider, announced that Centalion has deployed an AI Treasury Agent that lets treasury professionals run facility and trade finance instrument workflows through natural language, while keeping every control and approval step in place.
Centalion has relied on Komgo’s Konsole for over five years as the central platform for managing its off-balance sheet instruments across its banking counterparties. Even with digital platforms in place, the treasury team still had to move between systems to retrieve data, validate information and chase status updates.
Centalion’s response was to build and govern an AI Treasury Agent within its own cloud environment, combining a large language model with structured treasury workflows and facility-specific business rules.
The connection to Konsole runs through Komgo’s MCP (Model Context Protocol) connector, allowing Centalion to retain control of its AI and orchestration logic while securely interacting with Komgo’s trade finance infrastructure, with no point-to-point integration project required.
The first deployment covers Centalion’s off-balance sheet instrument syndicated facility and the early results are already tangible at the transaction level: issuance processing time has been cut by around 55%, and amendment processing time by around 80%. Once extended across Centalion’s full trade finance activity, this is projected to free more than 60 working days of treasury capacity each year, time that can be redirected toward risk oversight, facility optimization and financing strategy.
“We didn’t want to just build another chatbot. We wanted to change the way our Treasury team interacts with technical infrastructure. The agent can understand an instruction, apply our rules, and prepare a transaction in seconds while the decision remains with the people in the Treasury team. For us, this deployment demonstrates the real potential of agentic AI in a commodity trader’s Treasury department: removing friction without removing accountability”, commented Olivier Thevenon, Treasury Manager at Centalion.
“Centalion and Komgo are demonstrating how corporate treasury teams can build and govern their own AI capabilities on top of trusted, structured trade finance infrastructure, rather than replacing it,” said Baptiste Audren, Chief Revenue Officer at Komgo.
More about Centalion: https://centalion.com
More about Komgo: https://komgo.io
Press contact:
anne-sophie.pinson@komgo.io
Visit the Komgo Newswroom: https://www.komgo.io/newsroom
View original content:https://www.prnewswire.co.uk/news-releases/centalion-and-komgo-bring-agentic-ai-into-live-treasury-operations-302908521.html

- 0
- By Sai Krishna
14, Oct 2026
Huawei’s NG WAN Solution Enters Large-Scale Commercial Use to Drive Carrier Growth
VIENNA, Oct. 14, 2026 /PRNewswire/ — On October 13, at the Net5.5G Intelligent IP Network Summit during UBBF 2026, John Cai, Vice President of Huawei’s Data Communication Product Line, delivered a keynote speech, highlighting AI as a definitive opportunity in an uncertain future. He noted that the widespread deployment of the NG WAN Solution marks the full-scale commercialization of NG WAN. He stated that Huawei hopes to collaborate with industry stakeholders to continuously fortify a secure, resilient foundation and drive shared growth in the AI era.

Security & Resilience: Multi-Layered Defense
Huawei’s NG WAN Solution builds a multi-layered security system spanning device, link, and service layers. At the device layer, Huawei’s innovative RDR solution—powered by independent Threat Protection Units (TPUs) and a multimodal behavior expert algorithm—runs isolated from the router OS to detect over 95% of threats and trace APTs within minutes. On the data plane, Huawei’s proprietary NP and intelligent flow identification algorithm achieve 1:1 traffic inspection, detecting attacks in seconds and reducing DDoS risks by 90%. During over three months of use with a leading Chinese carrier, TPUs have thwarted 324 attacks from eight countries.
At the link layer, the PQC algorithm is supported on all Huawei devices in all scenarios, boosting encryption performance by 40%. The industry’s first built-in QKD solution enables three-channel integration, slashing network construction costs by 60% and breaking the 80 km transmission distance limit. Recently, Huawei and a carrier in Macao unveiled the world’s first quantum-secured target network, driving a 50% surge in private line revenue.
At the service layer, “1+4” defense-in-depth reduces border DDoS attack response from 1 minute to under 5 seconds. It improves unknown threat detection by 15%, achieves a 100% ransomware detection rate, and shortens threat handling to under 30 minutes via the CT-SOC.
Lossless Computing Efficiency: Unleashing Token Productivity
As AI increasingly advances into core business, intelligent computing is hyper-sensitive to packet loss—a mere 0.1% loss can slash computing efficiency by up to 55%. Huawei’s NG WAN Solution leverages AI Fabric to strengthen compute through network enhancements: The simplified two-layer multi-plane architecture expands network scale fourfold while reducing hardware usage by 30%. Network-wide NPLB achieves 98% link utilization and lifts training and inference performance by over 7%. For computing-network synergy, the Starnet lossless algorithm achieves zero packet loss for transmission over 1,000 km with more than 96% remote computing efficiency. This enables carriers to deliver a local-like experience, accelerating ToB monetization. The solution was deployed by a Chinese carrier to support a healthcare project, slashing hospital computing costs by 30% while driving a fivefold surge in private line ARPU.
Network Autonomy: AN L4 in Four Scenarios
Huawei’s “One Map, One Brain” autonomous network architecture achieves AN L4 across fault handling, network changes, network optimization, and security protection. Closed-loop automation is achieved for network changes spanning configuration verification, simulation, and comparison. Security protection enables intrusion detection, attack tracing, and one-click blocking within minutes.
Huawei has helped multiple carriers achieve AN L4, with a South African carrier becoming the world’s first to reach this level of autonomy on an IP network.
Over 60 carriers worldwide have deployed the NG WAN Solution. Through continuous innovation in lossless computing efficiency, multi-layered security, and network autonomy, the solution shifts carriers’ AI strategies from efficiency optimization to value creation, solidifying a secure, resilient network foundation for the AI era.
Looking ahead, Huawei will work with industry partners to expedite the global adoption of the NG WAN Solution, helping build secure, resilient, intelligent, and efficient next-generation bearer networks to drive carrier growth in the AI era.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/huaweis-ng-wan-solution-enters-large-scale-commercial-use-to-drive-carrier-growth-302908648.html

14, Oct 2026
Uzbekistan Hospitality Group TEG Completes U.S. Business Combination
Historic milestone positions TEG to capitalize on Uzbekistan’s rapidly expanding tourism market and execute its growth pipeline
NEW YORK, Oct. 14, 2026 /PRNewswire/ — TEG SPV LLC (“TEG”), a leading Uzbekistan-based, integrated hospitality, tourism and events business, today announced the successful completion of its business combination with StageWise Strategies Corp. (“STWI”), establishing the first U.S.-traded business from Uzbekistan.

The transaction was completed pursuant to a share exchange agreement under which TEG became the principal operating business of the combined public company. The company will operate as TEG Overseas, Inc. and its common stock will trade on the OTC Markets.
This milestone marks a significant step in TEG’s evolution and positions the company to capitalize on powerful secular trends shaping the region, including increasing international tourism visitation, expanding business travel, and continued investment in Uzbekistan’s economic and social development.
With established tourism industry expertise, TEG owns and operates a portfolio and ecosystem of premium hospitality and events assets in Uzbekistan, including Hilton Tashkent City, Wyndham Bukhara, and the Central Asian Expocenter (CAEx), one of Central Asia’s largest and most modern full-service convention centers for exhibitions and events. The portfolio generated $42.9 million in revenue and $14.4 million in net income in 2025, representing increases of 22% and 215%, respectively, from 2024.
“With a proven portfolio of high-quality assets, relationships with leading international hospitality brands, and a clear strategy for growth, TEG is well positioned for its next phase of development, which we expect will elevate TEG’s business aspirations and tangentially strengthen Uzbekistan’s national identity and competitiveness within the tourism sector,” said Anita Mendiratta, Chairperson of the Board of Directors of TEG. “TEG’s entry into the public markets comes at a pivotal moment for Uzbekistan’s greater visitor economy, as strong economic growth and an ambitious national development agenda are helping towards establishing the country as one of Central Asia’s most compelling and inviting tourism and business destinations.”
Positioned to Benefit from Uzbekistan’s Tourism Growth Trajectory
Uzbekistan welcomed approximately 11.7 million foreign tourists in 2025, an increase of nearly 47% from the prior year, and was ranked by UN Tourism among the world’s fastest-growing markets for international tourist arrivals in the first quarter of 2026. This momentum is underpinned by the country’s broader economic reform agenda and Uzbekistan 2030 strategy, which makes tourism a national priority supported by infrastructure development, expanded international connectivity, and private-sector growth.
Hospitality has been central to Uzbekistan’s culture for centuries, rooted in the country’s historic role as a crossroads of the Silk Road. Today, that heritage, together with the country’s ongoing modernization, investment in critical infrastructure linked to mobility and connectivity (including aviation and rail), and emergence as a regional investment hub, is helping establish Uzbekistan as an increasingly important destination for year-round, country-wide international tourism, business travel and events.
The AKFA Advantage
TEG is part of AKFA Group, one of Central Asia’s largest privately owned business groups, with 38,000 employees. Founded in Tashkent in 2001 by leading Uzbek entrepreneur Jakhongir Artikkhodjaev, AKFA operates businesses across seven strategic sectors: consumer electronics (Artel), aluminum profiles for doors and windows (AKFA), construction, healthcare, education, tourism and entertainment.
As part of the broader AKFA ecosystem, TEG benefits from:
- Global connectivity and trusted industry relationships
- Access to the largest and most experienced development and construction partners in the country
- Procurement efficiencies and operating scale advantages
- Faster execution and time-to-market for strategic initiatives
“Our longstanding relationship with AKFA has been integral to TEG’s development, providing access to the capabilities and relationships of a much broader business ecosystem,” said Irodakhon Abduvakhitova, Non-independent Director and Investor in TEG. “Combined with TEG’s proven sector expertise, these advantages enhance our ability to identify opportunities, execute efficiently, and scale our business across Uzbekistan and the broader region.”
Executing a Clear Growth Pipeline
As a public company, TEG intends to leverage access to the U.S. capital markets to support future acquisitions and expand its portfolio of hospitality and meetings, incentives, conferences, and exhibitions (MICE) assets. TEG plans to pursue acquisitions across its pipeline that expand its offerings and enable the company to serve a broader range of business and leisure travelers. TEG also intends to drive continued growth by leveraging its proven owner-operator model, deep knowledge of the Uzbek market, relationships with international hospitality brands and the development capabilities of the broader AKFA ecosystem.
Advisors
Kingswood ArcStone, a division of Kingswood Capital Partners, LLC, and Bluestone Investment Bank are serving as financial advisors to TEG. Ellenoff Grossman & Schole LLP and Dentons Uzbekistan are serving as legal counsel to TEG. Hunter Taubman Fischer & Li LLC is serving as legal counsel to StageWise.
About TEG
TEG is a leading, multi-dimensional tourism and hospitality business in Uzbekistan, building an integrated portfolio and ecosystem of hospitality, events and destination assets to serve the country’s fast-growing visitor economy. TEG’s portfolio includes Hilton Tashkent City, Wyndham Bukhara and the Central Asian Expocenter. As part of AKFA Group, one of Uzbekistan’s largest private groups of companies, TEG benefits from institutional scale, deep sector relationships and broader development capabilities. TEG’s growth strategy is focused on maximizing the potential of its existing portfolio while executing a pipeline of additional hospitality and tourism assets across Uzbekistan and the broader region. For more information, visit https://www.tegcompany.com/.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the federal securities laws, including statements related to TEG’s current views and expectations with respect to its future performance and operations, including revenues, earnings, cash flow and other financial and operating measures. Forward-looking statements are any statements other than statements of historical fact, including those that convey management’s expectations as to the future based on plans, estimates and projections at the time TEG makes the statements and may be identified by words such as “will,” “expect,” “believe,” “plan,” “anticipate,” “predict,” “intend,” “goal,” “future,” “forward,” “remain,” “confident,” “outlook,” “guidance,” “target,” “objective,” “estimate,” “projection” and similar words or expressions, including the negative version of such words and expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of TEG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
Factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, general economic conditions, including inflation, higher interest rates and potential recessionary pressures, which may impact decisions by consumers and businesses to use travel accommodations; global trade disputes, including with China; the performance of the financial and credit markets; the economic environment for the hospitality industry; operating risks in the hospitality business; TEG’s relationships with hotels, conference centers and other properties; the impact of war, terrorist activity, political instability or political strife; global or regional health crises or pandemics including the resulting impact on TEG’s business, operations, financial results, cash flows and liquidity, as well as the impact on guests and team members, the hospitality industry and overall demand for and restrictions on travel; TEG’s ability to satisfy obligations and agreements under its outstanding indebtedness, including the payment of principal and interest and compliance with the covenants thereunder; risks related to TEG’s ability to obtain financing and the terms of such financing, including access to liquidity and capital, as well as any risks reported in the reports filed by TEG with the Securities and Exchange Commission. These risks and uncertainties are not the only ones TEG may face and additional risks may arise or become material in the future. TEG undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law.


View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/uzbekistan-hospitality-group-teg-completes-us-business-combination-302908651.html

14, Oct 2026
Leonardo DRS Awarded JIATF-401 IDIQ Contract to Accelerate Delivery of Tactical Expeditionary Sensing Capabilities for Critical Counter UAS Mission
ARLINGTON, Va.– Oct. 14, 2026 – Leonardo DRS, Inc. (Nasdaq: DRS) announced today that it has been awarded a $500 million ceiling indefinite-delivery/
The JIATF-401 IDIQ is designed to increase speed and agility in delivering vetted Counter UAS (C-UAS) technologies and systems to operators. Under this contract, DRS will be eligible to compete for task orders that enable the rapid delivery of integrated C-UAS sensing capabilities supporting force protection and low-altitude air defense missions.
“Today’s threat environment is evolving faster than ever, and our customers need proven capabilities delivered at operational speed,” said John Baylouny, president and chief executive officer of Leonardo DRS. “This JIATF IDIQ positions DRS to accelerate the delivery of integrated C-UAS sensing technologies through rapid fielding of operationally relevant capabilities that help protect forces and strengthen low-altitude air defense as new threats emerge.”
“Our counter UAS and air defense radars have demonstrated proven detection, tracking, and force protection performance in operational environments,” said Max Cohen, senior vice president, general manager at Leonardo DRS RADA Technologies business unit. “We design, manufacture, and deliver combat-proven sensing systems at speed, and we’re ready now to support JIATF with mission-ready expeditionary radar capability that can be fielded rapidly as operational needs for C-UAS evolve.”
DRS manufacturers combat-proven radar and sensing solutions that support mission sets including counter-UAS, counter-rocket, artillery, and mortar, and short-range air defense, helping to provide persistent situational awareness and threat tracking for deployed forces. Backed by deep mission expertise and rapid design and manufacturing capabilities, the team supports customers from concept through production and sustainment to meet evolving threats with speed, scale, and reliability.
This IDIQ contract award positions DRS to compete for future task orders throughout the contract’s period of performance.
14, Oct 2026
Brainomix and Pulmonary Fibrosis Foundation Partner to Bring Patient Perspectives to AI-Powered Pulmonary Fibrosis Care
OXFORD, UK and CHICAGO, October 14th, 2026 – Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).
The partnership will focus on understanding patients’ perspectives when e-Lung quantitative CT analysis is incorporated into clinicians’ assessment workflow. The research will explore how access to objective quantitative CT metrics could enhance clinicians’ understanding of changes in disease over time, while examining how these insights are experienced and understood by patients. The initiative will also explore how these imaging insights could support more informed conversations between patients and their healthcare teams, including discussions around treatment decisions.
Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image analysis tool that provides automatic quantifications and visualizations of radiographic features in lung CT scans. Clinicians can use these outputs to aid in their diagnostic assessment of lung diseases.
With its deep connection to the PF and ILD community and extensive expertise in patient education, research and care, the PFF is uniquely positioned to help guide this initiative. The Foundation will draw on its patient and caregiver community and its understanding of both the clinical and lived experience of pulmonary fibrosis, helping ensure patient perspectives remain central to the programme. Through its Care Center Network, the PFF also connects medical centers with expertise in diagnosing and treating fibrotic lung diseases and in patient-oriented research.
The programme is part of PROGRESS-PPF, a broader research initiative between Brainomix and Boehringer Ingelheim, exploring the potential of quantitative CT imaging tools to provide objective metrics that support clinicians in their assessment of disease progression in patients with progressive pulmonary fibrosis. The new collaboration with the PFF builds on that work by bringing the patient perspectives to the forefront, exploring how these imaging insights can support meaningful conversations between patients and clinicians.
“Patients are at the heart of everything we are trying to achieve with e-Lung,” said Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix. “While our technology can provide new imaging tools for lung disease, we need to understand how those tools inform clinical understanding and how that information is communicated to and understood by the people living with the disease. Our partnership with the Pulmonary Fibrosis Foundation will help us listen directly to patients and caregivers and explore how AI-powered imaging tools can support greater understanding, communication and shared decision-making.”
The partnership will explore what patients want to know about their disease, how they respond to visual and quantitative outputs, and where e-Lung may provide the greatest value across their care. It will also explore how clinician imaging-derived insights could support conversations with patients about whether to start, continue or change treatment, particularly when changes in disease may not be evident from symptoms alone.
“People living with pulmonary fibrosis and their caregivers bring an essential perspective to the development of new approaches to understanding and managing this disease,” said Scott Staszak, President and CEO of the Pulmonary Fibrosis Foundation. “The PFF is deeply connected to the PF and ILD community and has a long-standing commitment to advancing research, education and care. We are pleased to partner with Brainomix to bring that patient voice and expertise into exploring how AI-powered quantitative imaging tools can be used in care. By listening directly to the community, we can better understand what information patients find valuable and how it can support conversations with their healthcare teams.”
The partnership reflects Brainomix and PFF’s shared commitment to further advancing a patient-centred approach to pulmonary fibrosis care, where new technologies are developed and evaluated with a clear understanding of the needs, experiences and priorities of the people they are intended to serve.
14, Oct 2026
Logitech Unveils Its Biggest Enterprise Launch Ever: More Power, More Future-Proofed Rooms for the AI Revolution
Dubai, United Arab Emirates — October 14, 2026 — Logitech has unveiled the largest enterprise product launch in company history, engineered to equip companies for the AI revolution. Headlined by Logitech Rally Bar 2, Rally System 2 Pro, and Sound Shape technology, the new portfolio brings advanced compute, intelligence and sensing into more workspaces to support the next decade of intelligent collaboration.
“This second generation of smart video collaboration devices is Logitech’s answer to a new, dual mandate for IT: Deliver exceptional meeting experiences today while preparing for an AI-powered tomorrow,” said Henry Levak, general manager of Team Workspace Solutions at Logitech.
“AI-powered workspaces will be most valuable when they make collaboration feel effortless and fit the way organizations actually work,” said Murad Ali, Head of Middle East & Central Asia, Logitech for Business. “For Middle Eastern organizations, where teams often collaborate across cities, countries and cultures, the next generation of intelligent meeting rooms can help every voice be heard, every space work harder, and every meeting feel more connected. Logitech’s new portfolio is an important step toward that future.”
Rally Bar 2: A Market Leader, Reinvented for the AI era
Rally Bar 2 is the successor to the industry-leading Rally Bar, now supercharged by a Qualcomm chipset that offers four times more edge AI processing power than various other video bars on the market.
A custom-designed lens and 1-inch sensor bring stunning visual clarity, and AI-powered Right Sound 3 brings studio-quality audio to meeting rooms. Embedded sensors automate the workplace by booking meetings when people walk in and provide occupancy data to help leaders make informed decisions about real estate.
With its sleek design, Rally Bar 2 can easily be installed by one person in just minutes. It is housed in an aluminum unibody for easier recycling.
Certified for Microsoft Teams, Zoom Rooms, and Google Meet, and built on Microsoft Device Ecosystem Platform (MDEP), Rally Bar 2 merges Microsoft’s enterprise-grade security standards with Logitech’s room intelligence and signature meeting experiences.
Rally System 2 Pro: Mastering Massive Spaces
A chronic pain point for IT is delivering quality, AI-driven meeting experiences in large, multi-purpose spaces–rooms. These spaces may constitute only a fraction of the building but consume the majority of IT effort. Logitech Rally System 2 Pro is a modular new solution that dramatically simplifies multi-vendor setups in complex and divisible rooms, making Logitech a one-stop-shop for all spaces, from small to extra-large rooms.
Introducing Sound Shape: Audio That Defies Expectations
High-value spaces like executive boardrooms and training rooms are historically tricky to outfit with audio. Logitech’s Rally Speaker 2 Pro and Rally Speaker 2 Max house groundbreaking new Sound Shape audio technology. Sound Shape uses focused acoustic beams to precisely direct sound toward listeners throughout the room. The result is evenly distributed sound across a 20-meter (about 65 feet) space–a feat only partially achieved previously by costly and complex ceiling speaker array installations.
Next-generation product highlights:
● Rally Bar 2: Video bar for medium to large rooms, with next-generation processing power; 4-speaker system, 6 beamforming mics, occupancy detection and environmental sensing.
● Rally System 2 Pro: Modular video conferencing system for large, complex, and divisible rooms, includes:
○ RoomMate 2 Pro: A Qualcomm-powered compute box running up to three 4K displays, multiple cameras, speakers, and mic pods across Android, PC, or BYOD setups.
○ Rally AI Camera Pro: A dual-camera device combining a wide-angle 1-inch sensor with Logitech’s legendary optical PTZ camera design.
○ Rally Speaker 2: Linear, 7-driver beaming networked speaker delivers the same volume and intelligibility in the back of the room as it does in the front.
○ Logitech Link: Native AV-over-IP tech that links Logitech devices using simple Category cables—no external extender and no PoE injectors.
○ Right Sight 3: Smarter multi-camera tracking that uses multiple wall-mounted or center-of-table cameras and angles to automatically capture the best view of the room.
● Rally Speaker 2 Pro: Soundbar with 32 micro-drivers evenly distributes sound throughout large rooms via Logitech’s new Sound Shape audio technology.
● Rally Speaker 2 Max: Soundbar with 64 micro-drivers evenly distributes sound throughout extra large 20m (65-foot) rooms via new Logitech’s unique Sound Shape audio technology.
Also new:
● Tap IP 2: Brighter, smarter, network-connected meeting room touch controller.
● Tap Scheduler 2: Room scheduling panel with brighter display, higher-resolution, upgraded compute and built-in motion sensor.
Pricing and Availability
Rally Bar 2, Tap IP 2, and Tap Scheduler 2 are rolling out globally now. Rally System 2 Pro, RoomMate 2 Pro, and the Rally Speaker 2 lineup will be available in Summer 2027. Right Sight 3 camera switching capability will be available in the second half of 2027 as a free CollabOS software update. For more details, please visit www.logitech.comor check with your local or online retailer.
14, Oct 2026
Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026
Stockholm, Sweden, October 14, 2026. Affibody AB (“Affibody”) today announced a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October 17-21 in Vienna.
The presentations span both clinical and preclinical research and include results from the ongoing Phase I study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer, clinical data with the HER2 PET imaging agent tezatabep matraxetan, and preclinical findings with Affibody molecules targeting B7-H3. Together, the presentations highlight the breadth of Affibody’s capabilities across targeted RLTs and precision imaging.
“The wealth and diversity of results being presented at EANM, one of the world’s leading congresses in nuclear medicine and theranostics, reflects both the potential of our Affibody technology and the strength of our collaborations,” said David Bejker, Chief Executive Officer of Affibody. “We are excited to see our science translate into meaningful advancements with the aim to address significant unmet needs in patients with hard-to-treat cancers.”
Presentations
Title: A First-in-Human Phase 1 Trial Safety and Biodistribution of [¹⁷⁷Lu]Lu-ABY-271 in Subjects with HER2-Positive Metastatic Breast Cancer (NCT07081555)
Presenter: Joachim Feldwisch, Affibody
Session: C: Therapy Clinical Study – C1 Oncological Therapy Clinical Study – C16 Other Oncological Treatments
Format: e-Poster
Presentation ID: EP-0981
Title: Whole-body HER2 PET/CT reveals spatial heterogeneity of HER2 expression in advanced gastroesophageal adenocarcinoma.
Presenter: Antonios Tzortzakakis, Karolinska Institutet
Date and Time: October 18, 2026, 08:00 CEST
Session: Clinical Oncology Track: Gastro-Intestinal Malignancy
Format: Oral
Presentation ID: OP-035
Title: Standardization of image quality and activity quantification in a multi-centre PET imaging study (Ex-PET)
Presenter: Jakob Lagerstedt, Karolinska University Hospital
Date and Time: October 20, 2026, 16:45 CEST
Session: Cutting Edge Science Track: Physics Committee: Quantitative PET:
Harmonisation and Robustness
Format: Oral
Presentation ID: OP-734
Title: Preclinical Evaluation of PNABased Affibody-mediated Pretargeting for targeting HER2: A direct comparison between Tb-161 and Lu-177
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 18, 2026, 09:45 CEST
Session: M2M Track: TROP Session – Radiopharmaceutical Sciences Committee: 161Tb vs 177Lu, and The Winner Is…
Format: Oral
Presentation ID: OP-084
Title: Modular Molecular Design of B7H3Targeting Affibody Molecules for Radionuclide Therapy: Biodistribution-Driven Selection and Therapy
Presenter: Maryam Oroujeni, Uppsala University
Date and Time: October 20, 2026, 16:45 CEST
Session: Radiopharmaceutical Sciences Committee: Modern Approaches to Drug Development in Nuclear Medicine
Format: Oral e-Poster
Presentation ID: EPS-223
Title: HER2-Ex PET trial: A multicentre, prospective, open-label study using [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2 antibody-drug conjugates in patients with metastatic breast cancer.
Presenter: Anna Kistner, Karolinska Institutet
Session: B: Imaging Clinical Studies – B1 Oncological Imaging Clinical Study – B13 Breast
Format: e-Poster
Presentation ID: EP-0261
Title: In vitro evaluation of Affibody molecules targeting B7-H3 for radionuclide therapy of neuroblastoma
Presenter: Maryam Oroujeni, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A11 In Vitro Studies
Format: e-Poster
Presentation ID: EP-0003
Title: Optimized Affibody Molecule targeting B7-H3 immune checkpoint: Improved Tumor Targeting Properties in a Syngeneic MC38 Model
Presenter: Enrique Recasens Pérez-Vera, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0171
Title: Feasibility of affibody-based pretargeted delivery of 225Ac
Presenter: Vladimir Tolmachev, Uppsala University
Session: A: Preclinical and Translational Studies – A1 Medical Preclinical – A18 New Radiopharmaceuticals – Therapy
Format: e-Poster
Presentation ID: EP-0161
Title: Biodistribution and dosimetry for PET imaging of HER2-receptor expression using [18F]-HER2 in metastatic breast cancer
Presenter: Ulrika Estenberg, Karolinska University Hospital
Session: B: Imaging Clinical Studies – B10 Dosimetry in Diagnostic Applications – B101 Dosimetry in Diagnostic Applications
Format: e-Poster
Presentation ID: EP-0617
View the EANM abstracts here: https://eanm26.eanm.org/
14, Oct 2026
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study
BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ — Continuity Biosciences, LLC, a clinical-stage biotechnology company developing precision drug delivery platforms, today announced it has been awarded an up to $9.6 million grant from the Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral (ARV) implant for HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMICs).

The implant is designed to deliver HIV prevention medicine continuously for multiple years after a single insertion under the skin. It is intended as an alternative to daily oral pills and to periodic injections, giving people at risk of HIV a prevention option that requires fewer dosing decisions and clinic visits.
The grant will support development of Continuity’s ultra-long-acting ARV implant through Investigational New Drug (IND)-enabling studies, submission of an IND application, and initiation of a Phase 1 first-in-human clinical study.
“For many people, the challenge in HIV prevention is not the availability of effective medicines, but the burden of staying protected consistently over time,” said Ramakrishna “Krishna” Venugopalan, PhD, MBA, Co-Founder and Chief Executive Officer of Continuity Biosciences. “A prevention option designed to provide protection for years could fundamentally change what is possible, particularly in communities where access to healthcare is limited.
Despite major advances in prevention, there were 1.2 million new HIV infections in 2025, according to UNAIDS. Daily oral PrEP is highly effective when taken as prescribed, but sustaining adherence remains difficult for many people. Long-acting injectables have extended dosing intervals, yet still require regular clinic visits bi-monthly or bi-yearly currently, and a dependable supply chain. These challenges are even greater in low- and middle-income countries.
Continuity’s implant builds on the company’s nanofluidic drug delivery technology, which uses precisely engineered channels to control drug release at a steady rate over an extended period. The approach is designed to sustain protective drug exposure over time while reducing the need for repeat dosing.
“Our nanofluidic implant was engineered around a simple idea: HIV prevention shouldn’t depend on remembering a daily pill or the next appointment,” said Alessandro Grattoni, PhD, Co-Founder and Chief Scientific Advisor of Continuity Biosciences. “By controlling drug release at the device level, we aim to sustain constant ARV delivery for multiple years from a single implant. This support allows us to move that science from the laboratory toward a first-in-human evaluation.”
As part of the grant, Continuity has made Global Access commitments to the Gates Foundation, including making the resulting technology available at an affordable price to people most in need in low- and middle-income countries and broadly sharing knowledge gained from the program.
Beyond HIV prevention, Continuity is applying its precision delivery platforms across type 1 diabetes, endocrinology, and oncology, including an ongoing first-in-human study of its iontophoretic oncology platform in pancreatic cancer.
About Continuity Biosciences
Continuity Biosciences is a clinical-stage biotechnology company developing precision drug delivery platforms for the controlled, sustained administration of therapeutics. Its technologies include intratumoral delivery systems for solid tumors, nanofluidic and subcutaneous long-acting implants, implantable devices for cell therapy, and microneedle systems for intradermal delivery. The company’s programs span oncology, type 1 diabetes, endocrinology, HIV prevention, and medical aesthetics. For more information, visit www.continuitybiosciences.com.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/continuity-biosciences-awarded-9-6-million-grant-to-advance-ultra-long-acting-implant-for-hiv-prevention-302907905.html

14, Oct 2026
IBM and Siemens Collaborate on Research to Advance Nanostack Architecture
Collaboration aims to accelerate development of the manufacturing and design capabilities needed for future nanostack generations
ALBANY, N.Y., Oct. 14, 2026 /PRNewswire/ — Today, IBM (NYSE: IBM), in collaboration with Siemens, announced new research aimed at advancing IBM’s nanostack architecture, a new transistor architecture unveiled by IBM earlier this year. The collaboration will bring together IBM’s leadership in semiconductor device innovation and Siemens’ expertise in electronic design automation (EDA), process simulation, lithography optimization, and advanced manufacturing software to accelerate the development of nanostack.

Nanostack is the industry’s first known three-dimensional, nanosheet-based design, vertically stacking and staggering transistors to pack more transistors onto a chip, with nearly 100 billion transistors in a space the size of a fingernail at its current 7 angstrom node. The design also unlocks the use of different material combinations within each stacked layer to optimize performance and power efficiency of each transistor independent of the other. These innovations power substantial leaps in energy efficiency, performance, and SRAM scaling.
Earlier this year, IBM demonstrated the viability of the nanostack architecture. Now, additional advances are needed to prepare the technology for manufacturing and production at scale.
Through this collaboration, IBM and Siemens will work to advance the design, simulation, and lithography techniques needed for this and future nanostack generations beyond the current 7 angstrom node. The collaboration includes developing advanced virtual models of nanostack in order to model performance, optimize designs, and address fabrication challenges before chips are built.
“Nanostack is a scalable transistor platform designed to shift device scaling from 2D to 3D, representing a new paradigm for the semiconductor industry and a path forward for the logic scaling needed to support AI and other emerging technologies over the coming decade,” said Huiming Bu, Vice President of Silicon Technology R&D, IBM. “We are thrilled to work with Siemens as we continue to advance this technology and explore new approaches to extend angstrom-level scaling with nanostack.”
“Scaling semiconductors into the angstrom era demands tightly coupled co-optimization between device physics, EDA design and manufacturing software, and manufacturing. As physical AI places extraordinary demands on silicon architecture, IBM’s 3D nanostack design represents a pivotal leap forward,” said Ankur Gupta, Executive Vice President, EDA IC Portfolio, Siemens. “Siemens’ collaboration with IBM to advance virtual modeling, simulation, lithography, and design software optimizations needed to address physical limitations early and accelerate the development of these complex architectures is truly pioneering.”
By combining IBM’s semiconductor leadership with Siemens’ advanced EDA software and simulation technologies, the companies aim to accelerate technology development cycles and advance the manufacturing foundation necessary for bringing nanostack toward production.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.
Media contact:
Willa Hahn
IBM Communications
willa.hahn@ibm.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ibm-and-siemens-collaborate-on-research-to-advance-nanostack-architecture-302907615.html

14, Oct 2026
Spinnaker Support Names Mark Fetches Global Chief Technology Officer
Expanded Role Unites Regional CTOs, Solution Consulting and Technical Account Management in One Global Organization
DENVER, Oct. 14, 2026 /PRNewswire/ — Spinnaker Support, the third-party software support leader entrusted by 1,300+ global clients, today announced the promotion of Mark Fetches to Global Chief Technology Officer (CTO). In the expanded role, Fetches brings the company’s regional CTOs, solution consulting team and technical account managers (TAMs) together into a single global organization. He will report to Chief Revenue Officer Pete Castello and join Spinnaker’s Go-to-Market Leadership Team, strengthening the connection between customer business priorities and Spinnaker’s technical sales and advisory capabilities.

“Customers choose Spinnaker for the expertise of our people,” said Matt Stava, CEO of Spinnaker Support. “Mark showed in EMEA how much customers value close technical engagement from the start. With him leading these teams globally, we can bring that same level of guidance to every region, helping customers solve immediate challenges and plan for what comes next.”
The new structure connects the technical guidance customers receive during evaluation with the expertise they rely on throughout their relationship with Spinnaker. Solution consultants who assess Oracle, SAP, VMware or PostgreSQL environments will now work alongside the TAMs and regional technology leaders who guide customers after the engagement begins. Iain Saunderson, chief technology officer for the Americas, will report to Fetches. Phil Wilkins, technical account manager and enterprise technical architect, and Sree Sakamuri, director of solution consulting, will also join Fetches’ organization.
Fetches previously served as Spinnaker’s CTO for EMEA, where he strengthened technical engagement with clients and connected their business priorities with Spinnaker’s capabilities. He brings more than 30 years of technology consulting and leadership experience from Accenture, Deloitte, and PwC. In those roles, he led customer-facing technical teams and advised C-suite executives and boards on digital, cloud, AI and enterprise transformation programs. Fetches is based in the UK and holds TOGAF and ITIL certifications.
“The best time to talk about modernization is before an upgrade or renewal forces the issue,” said Fetches. “That’s when customers have the greatest freedom to evaluate their options and move forward on their own terms. By bringing together our regional CTOs, solution consultants and technical account managers, we give customers access to the right expertise from the first conversation through execution.”
The promotion comes amid double-digit growth for Spinnaker, as more enterprises turn to independent support for greater control and flexibility. It follows several leadership appointments in 2026, including Rex Young as chief information officer in August and Vivek Pruthi as managing director for APAC. Spinnaker also promoted Martin Biggs to vice president and general manager of its PostgreSQL practice alongside the September launch of new PostgreSQL offerings to help enterprises reduce Oracle database dependency.
Resources:
- When AI Doesn’t Understand Your ERP
- How Madrilena Gas Ensured Stability and Savings with Spinnaker
- How Telkom Turned Oracle Support Savings into Digital Investment
- How a National Telecommunications Provider Stabilized Critical Systems and Reset Its IT Strategy
About Spinnaker Support
Spinnaker Support delivers independent third-party support and expert services for Oracle, SAP, VMware, and PostgreSQL environments. Its support, maintenance and modernization services help organizations run, optimize and transform their enterprise technology environments. It empowers customers to reduce vendor dependency and align technology strategies with business objectives. Spinnaker Support is trusted worldwide, including in highly regulated industries, giving organizations greater choice, control, and flexibility to unlock long-term value and transformation. For more information: www.spinnakersupport.com. Follow Spinnaker on LinkedIn.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/spinnaker-support-names-mark-fetches-global-chief-technology-officer-302907650.html
